SCYNEXIS, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.85
- 52-Week Range
- $2.70 – $9.12
- Market Cap
- $28.07M
- P/E (TTM)
- —
- EPS (TTM)
- -0.23
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.48
- PEG Ratio
- —
- Return on Equity
- -21.16%
- Return on Assets
- -25.16%
- Gross Margin
- 100.00%
- Operating Margin
- -126.86%
- Profit Margin
- -53.50%
- Current Ratio
- 7.57
- Debt/Equity
- 0.03
- Total Debt
- $1.82M
- Free Cash Flow
- $-6.90M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-17.28M
Market Snapshot
About
SCYNEXIS, Inc. is a biotechnology company focused on developing novel anti-infectives to address unmet medical needs. The company lead product candidate targets invasive fungal infections in immunocompromised patients who have limited or no treatment options.